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Background: Clinical studies suggest that hemodiafiltration (HDF) may lead to better clini-
cal outcomes than high-flux hemodialysis (HF-HD), but concerns have been raised about the 
cost-effectiveness of HDF versus HF-HD. Aim of this study was to investigate whether clinical 
benefits, in terms of longer survival and better health-related quality of life, are worth the pos-
sibly higher costs of HDF compared to HF-HD.
Methods: The analysis comprised a simulation based on the combined results of previous 
published studies, with the following steps: 1) estimation of the survival function of HF-HD 
patients from a clinical trial and of HDF patients using the risk reduction estimated in a meta-
analysis; 2) simulation of the survival of the same sample of patients as if allocated to HF-HD 
or HDF using three-state Markov models; and 3) application of state-specific health-related 
quality of life coefficients and differential costs derived from the literature. Several Monte Carlo 
simulations were performed, including simulations for patients with different risk profiles, for 
example, by age (patients aged 40, 50, and 60 years), sex, and diabetic status. Scatter plots of 
simulations in the cost-effectiveness plane were produced, incremental cost-effectiveness ratios 
were estimated, and cost-effectiveness acceptability curves were computed.
Results: An incremental cost-effectiveness ratio of 6,982/quality-adjusted life years (QALY) 
was estimated for the baseline cohort of 50-year-old male patients. Given the commonly accepted 
threshold of 40,000/QALY, HDF is cost-effective. The probabilistic sensitivity analysis showed 
that HDF is cost-effective with a probability of ∼81% at a threshold of 40,000/QALY. It is 
fundamental to measure the outcome also in terms of quality of life. HDF is more cost-effective 
for younger patients.
Conclusion: HDF can be considered cost-effective compared to HF-HD.
Keywords: cost-effectiveness, hemodialysis, hemodiafiltration
Introduction
Renal replacement treatment, in the form of kidney transplantation or dialysis, is a 
life-supporting therapy for patients with end-stage renal disease. At the end of 2010, 
∼1.81 million chronic kidney disease patients globally were undergoing hemodialysis 
(HD) treatment, with an estimated 90,000 (5%) thereof being treated with hemo-
diafiltration (HDF).1 Online HDF has been suggested as a possible cost-effective 
alternative compared to standard HD, mainly due to its superior middle molecule 
clearance resulting from the combination of diffusion and convection solute removal 
mechanisms. Several studies suggest that HDF may lead to better clinical results than 
high-flux HD (HF-HD).2,3 According to a recent survey, HDF was started to prevent 
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dialysis complications, increase the efficiency of dialysis for 
uremic accumulates, treat dialysis-related hypotension and 
dialysis-related amyloidosis, and for intractable pruritus, rest-
less leg syndrome and arthralgia not related to dialysis-related 
amyloidosis.4 However, to date, randomized studies have not 
conclusively supported the superiority of HDF regarding 
clinical outcomes.5–7 In addition, concerns have been raised 
about its cost-utility,8 leading investigators to conduct cost 
analyses to assess the differential expenditures between the 
two therapies.9 In a recent editorial, Vanholder et al concluded 
that more expensive therapies should be reimbursed only 
when evidence of their cost-utility, defined as the ratio of 
treatment cost to treatment outcome, taking into consider-
ation also the quality of life (QoL), is sufficiently robust.10 
The cost of HDF per se has decreased in recent years due to 
1) increased market penetration and the subsequent economy 
of scale in the production of equipment and disposables, 
2) the pressure on health care costs due to the economic crises 
prevailing since 2008, and 3) the safety and reliability of 
online method that have reduced demand for microbiological 
testing and monitoring.11,12 Furthermore, after the publication 
of the study of Canaud et al,2 HDF treatment effectiveness 
has increasingly been understood to be positively associated 
with the magnitude of the convection volume used, resulting 
in trends toward the application of higher HDF convection 
volumes than were applied in earlier cost analyses. Accord-
ingly, there is a need for a new cost-effectiveness evaluation. 
The aim of this study is to assess the cost-effectiveness of 
HDF compared to HD by a simulation using existing study 
data. These data facilitate an understanding of whether longer 
survival and better health-related quality of life (HRQoL) 
are able to offset the possibly higher costs of HDF, and thus 
whether it is worth investing in this more innovative therapy.
Methods
The analysis comprised a simulation13–15 based on results 
from combined previous observational studies, randomized 
clinical trials, and a meta-analysis with the following steps: 
1) estimation of a) the survival function of HF-HD patients 
from the Membrane Permeability Outcome Study16 dataset 
and b) estimation of the survival function of HDF patients 
using the risk reduction estimates due to the treatment effect 
from the meta-analysis of Mostovaya et al17 (even though 
it includes also studies comparing HDF to low-flux HD, it 
was considered the best proxy with respect to other alterna-
tive meta-analyses available in the literature); 2) simulation 
of the survival of the same sample of patients as if allo-
cated to HF-HD or HDF using three-state Markov models; 
3) application of state-specific HRQoL coefficients and 
differential costs (materials, testing, and consumption of 
water) derived from the literature. In addition, in a secondary 
subgroup analysis we considered the ESHOL5 estimations 
related to diabetics and nondiabetics. This was done because 
among all the studies considered the ESHOL study provides 
results related to these particular subgroups of patients. Two 
mirror-image Markov models (Figure 1) were developed with 
the aim to generate a simulation comparing the survival of 
the same sample of patients treated with HF-HD and HDF. 
Three possible states were considered: alive and under 
therapy, dead due to the disease under therapy, and dead for 
other cause (ie, considering the overall mortality, based on 
age- and sex-adjusted life tables).
HF-HD
HF-HD costs
HF-HD HRQoL weights
Death Death
Death from
other cause
Death from
other cause
Treatment
effect
HDF
HDF costs
HDF HRQoL weights
Figure 1 Structure of the Markov model.
Abbreviations:+')KHPRGLDÀOWUDWLRQ+)+'KLJKÁX[KHPRGLDO\VLV+54R/KHDOWKUHODWHGTXDOLW\RIOLIH
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The probabilities defining the transition of patients 
between each of these states were calculated from the 
previously estimated hazard functions and were specified 
over a defined time frame (cycle). The model was run for 
a specified number of cycles to see how the hypothetical 
cohort of patients moved between states. The length of the 
cycle was fixed to 1 year and the number of cycles to ten, 
for a total of 10 years. Each state of the model was associ-
ated with a HRQoL coefficient and a cost. The costs were 
considered from a societal perspective. Accordingly, total 
dialysis costs can be divided into: 1) direct health care costs, 
such as staff, material, vascular access, routine diagnostics, 
hospitalization, drugs, and medications; 2) direct nonhealth 
care costs, such as cost of transport and cost of informal care; 
and 3) indirect nonhealth care costs, productivity losses due 
to disability or premature death. It is reasonable to assume 
that direct nonhealth care costs and indirect nonhealth care 
costs are the same for the two therapies, and also that most 
of the direct health care costs do not vary by treatment. As 
a consequence, the comparison on the incremental costs of 
HDF with respect to HF-HD focused only on the costs of 
equipment, disposables, ultrapure water testing, and water 
consumption.18 In order to obtain more generalizable results, 
we analyzed two alternative cost settings, involving or not 
involving the use of ultrapure water. The first was based on 
the assumption that, since dialyzers used to perform both 
HDF and HF-HD are designed to have better solute clear-
ances on a wider range of uremic toxins and higher hydraulic 
permeability, it is reasonable to argue that the same water 
and dialysis fluid microbiological purity were necessary 
for both therapies due to backfiltration phenomena, lead-
ing to similar costs of water testing. As a consequence, 
and because differences in total water consumption are 
negligible, it was possible to limit the analysis to the costs 
of disposables (blood lines, dialyzers) and equipment only. 
In the prospective observational study by Oates et al,9 
some patients on HF-HD were switched to HDF and others 
remained on HF-HD. They were then prospectively followed 
for 12 months. The additional cost of disposables related to 
HDF was of 1.32 per session (207 per annum [p.a.]) in the 
standard case, that is, with the use of a cuvette for relative 
blood volume monitoring. The alternative cost setting was 
based on the analysis by Lebourg et al12 where, in addition 
to a cost variability due to disposables and monitors, the dif-
ference in cost between the two different therapies caused by 
water analysis and water consumption was considered. The 
additional HDF cost per session ranged from a minimum 
value of −1.29 (−202 p.a.) to a maximum value of 4.86 
(730 p.a.). Once the relevant costs were determined, the cor-
responding estimated and discounted costs (or a differential 
cost) taken from the literature were allocated to each state of 
the model.
Contradicting results have been reported on the difference 
in QoL related to HF-HD and HDF. Few studies addressed 
the QoL evaluation, and none provided HRQoL coefficients 
for the specific comparison of HF-HD and HDF, fundamental 
for the purpose of this analysis. Mazairac et al8 estimated 
higher scores with Euroqol 5D for patients on HDF com-
pared with HD. This preference-based measure yields a set 
of weights on which quality-adjusted life years (QALYs) 
calculations can be based. In this study, the comparison was 
made between HDF and low-flux HD. As there are no other 
data about QoL differences between HDF and HF-HD in the 
literature, these coefficients have been used in our simula-
tion. In particular, the HRQoL coefficients linked to age 
were selected for the model because otherwise a fundamental 
component of the benefit measurement would have been 
neglected.
As recommended by the economic analysis guidelines,19 
an annual discount rate of 3.5% for both costs and benefits 
was selected, and changes in results as a function of differ-
ent values of these parameters were considered. Parameter 
uncertainty was included in the model through a probabi-
listic sensitivity analysis, taking the intrinsic imprecision 
of the estimate of the parameters of the survival model into 
account. Consequently, the quality and quantity of informa-
tion available can be reflected in the probability distributions 
assigned to each input parameter in the model.20 Several 
Monte Carlo simulations were performed, also for patients 
with different risk profiles by age (patients aged 40, 50, 
and 60 years), sex, and diabetic status.21,22 For the sake of 
simplicity, the cohort of simulated 50-year-old male patients 
were selected as the reference population for the analysis. 
As discussed in the next section, we found similar results 
in all age subgroups, with identical conclusions in terms of 
cost-effectiveness; therefore, we used this cohort to briefly 
recap the main results of our analysis. The characteristics 
of this cohort are coherent with the results from the EDTA 
registry reported by van de Luijtgaarden et al:23 in the last 20 
years indeed the mean age of patients who started with HD 
treatment was 55–60 years, and on average >60% of patients 
were male.
Output analyses included scatter plots of simulations in 
the cost-effectiveness plane, the estimation of incremental 
cost-effectiveness ratios (ICERs) and the computation of 
cost-effectiveness acceptability curves (CEACs).
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Results
The results of the 1,000 Monte Carlo simulations for the cohort 
of 50-year-old male patients are shown in the cost-effectiveness 
scatter plot in Figure 2. From the mean values of all the simula-
tions in this specific cohort of patients, the ICER was 6,982/
QALY. On the basis of these simulations it was possible to 
derive the probability of cost-effectiveness given different 
thresholds, as shown in Figure 3. The CEAC corresponding to 
HDF starts from 0, meaning that there is no possibility that this 
alternative therapy is cost-saving. The threshold must be at least 
2,000 per QALY to have a probability of cost-effectiveness >0. 
The probability of cost-effectiveness increased to 50% with a 
threshold of 7,000/QALY, to 70% with a threshold of 15,000/
QALY and to 81% with the commonly accepted threshold of 
40,000/QALY. The probability of cost-effectiveness always 
stayed below 84% for a threshold of over 40,000/QALY. This 
asymptotic value results from the fact that a fraction of the 
simulations represent cases where the alternative therapy (HDF) 
causes higher costs and provided fewer benefits. This means that 
even with any budget constraint, there is some probability that 
the alternative therapy is not cost-effective and the traditional 
one (HF-HD) is preferred.
The same analyses were carried out for the subgroups 
of 40-, 50-, and 60-year-old male and female patients 
Figure 2 Cost-effectiveness plane for 50-year-old male patients.
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Figure 3 &RVWHIIHFWLYHQHVVDFFHSWDELOLW\FXUYHVIRUPDOHSDWLHQWVDJHG\HDUVROGWUHDWHGZLWKKLJKÁX[+'RURQOLQH+')
Abbreviations:+')KHPRGLDÀOWUDWLRQ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compared to the quantitative one (life years). The effect of 
using overall HRQoL coefficients (rather than the HRQoL 
coefficients linked to patient age) on the cohort of 50-year-old 
male patients is shown in Figure 5. The mean ICER increased 
to 19,423/QALY but, more importantly, almost 37% of the 
simulations were on the left of the QALY zero value (less 
effectiveness, more costs) and, accordingly, the uncertainty 
around the decision whether to invest in the new therapy was 
much higher. Even an infinite value of the threshold would 
not lead to a probability of cost-effectiveness >65% (data not 
shown). This is caused by the uncertain values of the overall 
HRQoL coefficients, leading to some cases where one period 
spent under HF-HD is worth even more than the same period 
under HDF. This shows that it is crucial to consider the role 
of QoL is in such evaluations.
Using the alternative cost setting, the model becomes 
fully probabilistic. Previously, cost inputs were point esti-
mates, whereas now costs vary over the range assessed by 
Lebourg et al.12 The CEAC for the subgroup of 50-year-old male 
patients shows that 21.5% of the simulations are cost-saving 
(Figure 6). The probability of being cost-effective reaches 80% 
at the commonly accepted threshold of 40,000/QALY, and it 
increases only by 2.4 percentage points even with a threshold 
of 70,000/QALY. Results are consistent with the previous cost 
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 Figure 4 &RVWHIIHFWLYHQHVVDFFHSWDELOLW\FXUYHVIRUIHPDOHDQGPDOHSDWLHQWVDJHGDQG\HDUVRQKHPRGLDÀOWUDWLRQ
(Table 1): HDF appears to be more cost-effective for younger 
patients. This message is reinforced in Figure 4, which shows 
that a given threshold value is associated to a higher prob-
ability of HDF being cost-effective for the 40- and 50-year-
old patients than for the 60-year-old ones. Moreover, for the 
60-year-old groups there is a probability of around 28% for 
both females and males that HDF is not cost-effective even 
at extreme values of the threshold.
Regarding the discount rates for costs and benefits, results 
were robust even after considering alternative scenarios with 
lower or higher discount rates. By applying a 0% or a 5% dis-
count rate for both costs and effects, 50-year-old male patient 
ICER decreased to 6,676/QALY and increased to 6,960/
QALY, respectively, confirming the robustness of the estimations.
A further analysis was performed to investigate the 
importance of the qualitative component of the QALYs (QoL) 
Table 1,QFUHPHQWDOFRVWVDQG4$/<VIRUVXEJURXSVRISDWLHQWV
Males, age, years Females, age, years
40 50 60 40 50 60
Incremental cost () 1,679 1,653 1,538 1,707 1,701 1,641
,QFUHPHQWDO4$/<V 0.293 0.237 0.112 0.290 0.248 0.120
ICER (/QALY) 5,732 6,982 13,668 5,878 6,872 13,697
Abbreviations:,&(5LQFUHPHQWDOFRVWHIIHFWLYHQHVVUDWLR4$/<VTXDOLW\DGMXVWHG
life years.
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Figure 6 &RVWHIIHFWLYHQHVVDFFHSWDELOLW\FXUYHVIRUIHPDOHDQGPDOHSDWLHQWVDJHGDQG\HDUVRQKHPRGLDÀOWUDWLRQDOWHUQDWLYHFRVWVHWWLQJ
setting. With regard to the mean ICERs, HDF seems a little 
more expensive: for instance, the ICERs of the younger patients 
rise from 5,878/QALY and 5,732/QALY to 7,748/QALY 
and 7,724/QALY for female and male patients, respectively 
(Table 2). This subgroup analysis confirmed the previous 
results: the ICER increases with the age of the cohort.
C
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Figure 5 &RVWHIIHFWLYHQHVVSODQHIRU\HDUROGPDOHSDWLHQWVXVLQJRYHUDOOKHDOWKUHODWHGTXDOLW\RIOLIHFRHIÀFLHQWV
Abbreviation:4$/<VTXDOLW\DGMXVWHGOLIH\HDUV
Diabetic patients follow a different survival function and 
are subject to a different treatment effects of the alternative 
therapy compared to nondiabetic patients. Diabetics are 
characterized by a higher mortality risk and a lower treatment 
effect. Nevertheless, the comparison between a cohort of 
50-year-old diabetic male patients and a cohort of 50-year-old 
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nondiabetic male patients did not reveal significant differ-
ences (Figure 7).
Discussion
Given the commonly accepted threshold of 40,000/QALY, 
this study demonstrated that, compared to HF-HD, HDF is 
a cost-effective treatment for patients on dialysis. This is 
particularly true for patients <60 years, irrespective of sex or 
diabetic status. Either way, the variability in the results due to 
different characteristics of the patients does not affect the con-
clusions about the cost-effectiveness of HDF. These results are 
quite different from those reported by Mazairac et al8 in their 
cost-utility analysis of HDF versus conventional low-flux 
HD based on the unadjusted results for convective volume 
of the CONvective TRAnsport STudy (CONTRAST).7 Their 
estimated incremental cost per quality-adjusted life year of 
HDF compared to low-flux HD was 287,679 and certainly 
not below 140,000 under the most favorable assumptions 
(eg, applying a convection volume >20.3 L). They argued that 
the HDF is characterized by higher cost and better health and 
was not cost-effective given the currently accepted cost-utility 
thresholds. However, it has to be mentioned that the same 
analysis performed on patients treated in Montreal (Canada) 
according to the same protocol yielded different, positive, 
results.24 Our analysis, on the other hand, reports that HDF is 
cost-effective with a probability of ∼81%. This conclusion is 
based on what is considered the commonly accepted threshold 
for health policy decisions,25 which is ∼40,000 (or 30,000 
GBP, or 50,000 USD) per QALY. Even if this threshold is 
difficult to quantify and is often based on a rule of thumb, 
it is commonly applied as an estimate of the forgone health 
resulting from services displaced to accommodate the addi-
tional costs of the new technology. Of note, the magnitude 
of the difference between the two studies may be related to 
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Figure 7 Cost-effectiveness acceptability curves for diabetics and nondiabetics.
Table 2,QFUHPHQWDOFRVWVDQG4$/<VIRUVXEJURXSVRISDWLHQWV
DOWHUQDWLYHFRVWVHWWLQJ
Males Females
40 50 60 40 50 60
Incremental cost () 2,062 2,097 1,927 2,226 2,213 2,183
,QFUHPHQWDO4$/<V 0.267 0.238 0.106 0.287 0.245 0.110
ICER (/QALY) 7,724 8,825 18,206 7,748 9,050 19,880
Abbreviations:,&(5LQFUHPHQWDOFRVWHIIHFWLYHQHVVUDWLR4$/<VTXDOLW\DGMXVWHG
life years.
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the different comparison groups, which is low-flux HD in the 
CONTRAST study and HF-HD in our model.
The ICER estimates show a good value for money, 
but some doubts about the cost-effectiveness of HDF over 
HF-HD remain due to the residual ∼20% probability of costs 
being higher and/or benefits being lower with HDF. This line 
of reasoning is also shared by McBrien and Manns26 in their 
commentary of the Mazairac study, where they argued that 
HDF is characterized by higher procedural costs and has 
no proven health benefit. Our study specifies that the sur-
vival difference is not the only important factor (especially 
considering the lack of agreement on this aspect), but that 
differences in terms of QoL are of fundamental importance 
and must be measured. This was the rationale for conducting 
a value-based study incorporating HRQoL as a main out-
come of HDF versus HF-HD. Convective treatments as HDF 
indeed reduce intradialytic hypotension (which affects QoL), 
and possibly limit the poor appetite and nutritional state in 
patients with chronic kidney disease. However, we believe 
that more research is warranted to assess the impact of HDF 
specifically on the nutritional state of end-stage renal disease 
patients. Therefore, this study recommends prioritizing the 
research which evaluates the QoL related to HDF.
It must be stressed that the purpose itself of an economic 
decision model is to synthesize all the relevant evidence in 
order to make a sense of it and inform the decision about 
the adoption of a new technology in an uncertain context.15 
We have indeed identified the relevant studies involving the 
therapies under assessment, and we have included all the 
uncertainty in our parameter estimates, without neglect-
ing any relevant information in the literature. Our result 
is therefore based on published data, but its accuracy is 
sensitive to some decisions that we were forced to take in 
the model construction phase. The first decision was to use 
survival estimates from the HF-HD arm of the Membrane 
Permeability Outcome16 randomized clinical trial. This trial 
was based on incident patients, whereas other studies on 
HDF were mainly performed on prevalent European dialysis 
patients. Additionally, the low crude mortality rate observed 
in the Membrane Permeability Outcome study may produce 
results not completely transferrable to ordinary (nontrial 
participating) patients. Indeed, as stressed by Palmer et al,20 
relative risk reductions applied to low baseline risks produce 
low absolute reduction in event rates and low gains in health. 
It is possible that this low overall mortality rate affected the 
lack of difference between diabetic and nondiabetic patients. 
The reproducibility of the estimates remains therefore to be 
interpreted with caution.
The second point of discussion is the source of the 
effect estimators. As previously stressed, one of the main 
 requirements for an economic evaluation is to include all 
the relevant evidence. With regard to the effectiveness data, 
this concept does not change, and meta-analysis is the usual 
technique employed to synthesize all the available evidence. 
To date five meta-analyses aggregating the results of the main 
convective dialysis therapy studies17,27–30 have been published. 
However, a huge heterogeneity of interventions was included 
in these meta-analyses, and the meta-analysis by Mostovaya 
et al17 was the only one which focused on trials on HDF as 
convective therapy with appropriate definition of convective 
volume. This was the basis for considering the related relative 
risk estimations in this model. Nevertheless, there is still a 
great variety of patients and treatment modalities character-
istics among the studies. Indeed, for instance, both high- and 
low-flux modalities were included in the comparison. As a 
consequence, a relative risk based on a random effects model 
has been used, which makes the estimate of the pooled effect 
more conservative, and takes into account the clinical hetero-
geneity among the single studies. Of note, this meta-analysis 
includes also the CONTRAST study, and our cost-effective-
ness analysis does include all the relevant randomized clinical 
trials. On the contrary, for instance, the economic evaluation 
by Mazairac is based only on the CONTRAST study; this 
is a subjective decision, while a complete cost-effectiveness 
analysis should instead take into consideration all the relevant 
available evidence, as previously pointed out.
With regard to the subanalysis of the diabetic patients, 
the ESHOL5 estimates of risk reduction have been used. As 
the ESHOL study provided the most positive results in favor 
of HDF, concerns about the overestimation of the reduction 
in mortality could be raised. Nevertheless, the model did 
not show any difference between the two groups of patients, 
and this result highlights again that the impact on mortality 
is less important than the effect on the QoL.
Other limits for the current study have to be considered. 
The estimations used for this study were mainly derived from 
a meta-analysis with basically 2–3 years follow-up time, but a 
more appropriate time horizon would be the patient’s lifetime. 
This is especially true in the case of treatment of chronic dis-
eases where the initiation of an intervention in middle-aged 
patients may have cost and effect implications on the rest of 
their lives.31 An important role of a decision model, therefore, 
is to bridge the gap between what has been observed in trials 
and what would be expected to happen over the long-term, 
forcing one to make assumptions about the long-term effects 
and consequences of treatment modalities. Additionally, the 
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lack of QoL coefficients related to HF-HD forced the use of 
data from a comparison of HDF with low-flux HD.8
Conclusion
On the basis of this simulation HDF can be considered 
cost-effective. Uncertainty around results is high, but this 
is typical in this kind of analyses: neglecting some available 
evidence only because of its uncertainty would contrast with 
the comprehensive nature of an economic model. This study 
contributes also to show the scarcity and heterogeneity of 
data available in the literature that jeopardize the economic 
evaluation of HDF when compared to HF-HD. New studies 
are needed to assess more precisely the differential benefits 
between the therapies: value-of-information analysis might 
help to identify more specifically the parameters which 
would be worth to be further investigated. A more compre-
hensive evaluation performed in a randomized clinical trial 
is required in order to include other relevant cost components 
(eg, pharmaceuticals, hospitalizations, prevention of long-
term dialysis-related complications, beta-2 microglobulin-
amyloidosis, and transplantation access) in the analysis. 
Possible savings resulting from a reduction in the cost of 
ancillary pharmacological therapy and hospitalization have 
not been considered in the current analysis.
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